Since the neonatal IgG Fc receptor (FcRn) was discovered, it was found to be involved in immunoglobulin recycling and biodistribution, immune complexes routing, antigen presentation, humoral immune response, and cancer immunosurveillance. The latest data show that FcRn plays a part in cancer pathophysiology. In various types of cancers, such as lung and colorectal cancer, FcRn has been described as an early marker for prognosis. Dysregulation of FcRn expression by cancer cells allows them to increase their metabolism, and this process could be exploited for passive targeting of cytotoxic drugs. However, the roles of this receptor depend on whether the studied cell population is the tumor tissue or the infiltrating cells, bringing forward the need for further studies.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Cadena Castaneda, D., Brachet, G., Goupille, C., Ouldamer, L., & Gouilleux-Gruart, V. (2020, July 1). The neonatal Fc receptor in cancer FcRn in cancer. Cancer Medicine. Blackwell Publishing Ltd. https://doi.org/10.1002/cam4.3067